benzo(a)pyrene has been researched along with Cardiomegaly in 3 studies
Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.
benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We recently demonstrated that benzo(a)pyrene (BaP) causes cardiac hypertrophy by altering arachidonic acid metabolism through the induction of the expression of CYP ω-hydroxylases and soluble epoxide hydrolase (sEH) enzymes." | 3.77 | Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. ( Aboutabl, ME; El-Kadi, AO; Hammock, BD; Zordoky, BN, 2011) |
| "There is a strong correlation between cytochrome P450 (P450)-dependent arachidonic acid metabolism and the pathogenesis of cardiac hypertrophy." | 3.75 | 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. ( Aboutabl, ME; El-Kadi, AO; Zordoky, BN, 2009) |
| "Therefore, the mechanism of the cardiac hypertrophy caused by BaP exposure during early life stages may be through inducing the expression of CdC42, RhoA and Rac1, together with activating ERK1, 2." | 1.40 | Exposure to low dose benzo[a]pyrene during early life stages causes symptoms similar to cardiac hypertrophy in adult zebrafish. ( Gao, D; Huang, L; Wang, C; Zhang, Y; Zuo, Z, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L | 1 |
| Gao, D | 1 |
| Zhang, Y | 1 |
| Wang, C | 1 |
| Zuo, Z | 1 |
| Aboutabl, ME | 2 |
| Zordoky, BN | 2 |
| El-Kadi, AO | 2 |
| Hammock, BD | 1 |
3 other studies available for benzo(a)pyrene and Cardiomegaly
| Article | Year |
|---|---|
Exposure to low dose benzo[a]pyrene during early life stages causes symptoms similar to cardiac hypertrophy in adult zebrafish.
Topics: Animals; Base Sequence; Benzo(a)pyrene; Cardiomegaly; DNA Primers; Dose-Response Relationship, Drug; | 2014 |
3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats.
Topics: Animals; Arachidonic Acid; Benzo(a)pyrene; Cardiomegaly; Chromatography, Liquid; Cytochrome P-450 En | 2009 |
Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene.
Topics: Animals; Arachidonic Acid; Benzo(a)pyrene; Biomarkers; Cardiomegaly; Cardiotonic Agents; Cytochrome | 2011 |